Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Wilmington, North Carolina 28412


The purpose of this study is to see how the body processes 1592U89 and ethanol (pure grain alcohol) when they are given together.

Study summary:

Patients are randomized to one of the following three regimens: Regimen 1: 1592U89 alone. Regimen 2: pure grain alcohol diluted in orange juice. Regimen 3: 1592U89 plus pure grain alcohol diluted in orange juice. Treatment is administered weekly for 3 weeks.


Inclusion Criteria Concurrent Medication: Allowed: - Local treatment for Kaposi's sarcoma. - Prophylactic treatment for opportunistic infections. Patients must have: - HIV-1 infection. - CD4+ lymphocyte count >= 200 cells/microliter within 14 days prior to study drug administration. - No active diagnosis of AIDS (other than visceral Kaposi's sarcoma) according to the 1993 Centers for Disease Control and Prevention (CDC) AIDS surveillance definition. Prior Medication: Allowed: Local treatment for Kaposi's sarcoma. Exclusion Criteria Co-existing Condition: Patients with the following symptoms and conditions are excluded: Malabsorption syndrome or other GI dysfunction which may interfere with drug absorption. Concurrent Medication: Excluded: - Medications that cannot be withheld for 48 hours (24 hours for antiretrovirals) prior to study drug administration and until 12 hours after study drug administration on each dosing day. - Immunomodulators, such as systemic corticosteroids, interleukins and interferons. - Cytotoxic chemotherapeutic agents. - Acute treatment for opportunistic infections. Concurrent Treatment: Excluded: Radiation therapy. Patients with the following prior conditions are excluded: - Documented history of alcoholism. - History of clinically relevant hepatitis or pancreatitis within 6 months prior to study drug administration. - History of hypersensitivity, anaphylactic, or idiosyncratic reaction to nucleoside analogs. - Participation in another research study within the past month. Prior Medication: Excluded: - Cytotoxic chemotherapeutic agents within six weeks prior to study drug administration. - Immunomodulating agents within six weeks prior to study drug administration. - Treatment with the following within 2 weeks prior to study drug administration: - acyclovir, carbamazepine, chloramphenicol, ganciclovir, phenytoin, rifampin, sodium valproate, or valacyclovir. Prior Treatment: Excluded: Radiation therapy within 6 weeks prior to study drug administration. 1. Regular weekly alcohol intake of more than 21 units (a unit is equal to 1/2 pint beer or 1 glass of wine or 1 oz of liquor). - Recent change in normal pattern of alcohol usage (e.g., prolonged use followed by > one month abstinence). - Total abstinence from alcohol use. - Positive breath alcohol test upon arrival at the study center prior to any dosing day.

Study is Available At:

Original ID:




Secondary ID:

CNAA 1010

Study Acronym:

Brief Title:

A Study of 1592U89 and Ethanol When Given Together to HIV-Infected Patients

Official Title:

A Study to Investigate Whether There is a Pharmacokinetic Interaction Between 1592U89 and Ethanol Following Their Co-Administration to HIV-Infected Subjects.

Overall Status:


Study Phase:

Phase 1



Minimum Age:

18 Years

Maximum Age:

55 Years

Quick Facts

Healthy Volunteers
Oversight Has DMC
Study Is FDA Regulated
Study Is Section 801
Has Expanded Access

Study Source:

NIH AIDS Clinical Trials Information Service

Oversight Authority:

United States: Food and Drug Administration

Reasons Why Stopped:

Study Type:


Study Design:

Masking: Open Label, Primary Purpose: Treatment

Number of Arms:


Number of Groups:


Total Enrollment:


Enrollment Type:

Study Dates

Verification Date:August 1997
Last Changed Date:June 23, 2005
First Received Date:November 2, 1999

Study Outcomes

There are no available Study Outcomes

Study Interventions

Intervention Type:Drug
Name:Abacavir sulfate

Study Arms

There are no available Study Arms

Study Agencies

Agency Class:Industry
Agency Type:Lead Sponsor
Agency Name:Glaxo Wellcome

Sample and Retention Information

There are no available Sample and Retention Information

Study References

There are no available Study References

Data Source: ClinicalTrials.gov

Date Processed: January 21, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

This study is not currently recruiting Study Participants. The form below is not enabled.